Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis.

Published in: Therapeutic advances in musculoskeletal disease (2022)

While preliminary, our results could provide a good starting point to develop a predictive tool to limit adverse events during this therapy.

Keyphrases